ReviewACS applied materials & interfaces2025
Advances in Ultrasmall Inorganic Nanoparticles for Nanomedicine: From Diagnosis to Therapeutics.
Review in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nanomaterial-Based Precision Drug Delivery for Advanced Nephrology Therapy: A Systematic Review.International journal of nanomedicine · 2026Pooled it
- Can nanozymes make the leap to the clinic? Advances, hurdles, and prospects.Trends in biotechnology · 2026Review
- Navigating a thorny path: oral nanomedicines for the precision management of radiation-induced intestinal injury.Journal of nanobiotechnology · 2026Review
- Peptide-Functionalized Gold Nanorods as a Model to Reach the Cell Nucleus: Synthesis and Structural Characterizations in View of Theragnostic Applications.The journal of physical chemistry. B · 2026Article
- Advances in nano-delivery systems for overcoming the challenges of applying siRNA drugs in tumor therapy.Asian journal of pharmaceutical sciences · 2026Review
- Nanodelivery of Traditional Chinese Medicine Monomers: An Emerging Strategy to Reprogram the Immunosuppressive Tumor Microenvironment.International journal of nanomedicine · 2026Review
- Theranostic Nanoprobes for Rheumatoid Arthritis: From Inflammation Visualization to Guided Precision Therapy.International journal of nanomedicine · 2026Review
- Multifunctional gold nanoclusters as next-generation theranostic platforms for disease management.International journal of pharmaceutics: X · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Inorganic nanoparticles possess unique physicochemical properties that make them attractive candidates for diverse applications in nanomedicine, including as contrast agents and as therapeutics. However, many inorganic nanoparticles are composed of high-atomic-number elements, raising safety concerns due to potential long-term retention in the body. However, ultrasmall inorganic nanoparticles (UINPs), i.e., those that are less than ∼5 nm in diameter, can offer the advantage of rapid renal clearance from the body, reducing toxicity risks associated with prolonged exposure and thereby creating a path toward clinical translation. In this review, we discuss current knowledge on the design and functionalization of UINPs, exploring their capabilities from diagnosis to therapeutics, with examples including radiosensitization, photothermal, and anti-inflammatory catalytic therapies. In addition, we discuss their limitations, the approaches taken to solve their limitations, and progress of UINPs toward clinical translation. Through this discussion, we aim to provide a comprehensive perspective on how UINPs are advancing the field of nanomedicine, underscoring their potential to significantly improve bioimaging and therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.